Angiotensin-converting enzyme (ACE) activity in the myocardium and angiotensin-II (Ang-II) levels in plasma increase after myocardial ischemia, which lead to exacerbation of myocardial injury and cardiac dysfunction. We examined the protective role of novel antisense-oligodeoxynucleotide (AS-ODN) directed at ACE mRNA in myocardial ischemic injury. Sprague-Dawley rats were treated with ACE-AS-ODN (200 g per rat, n = 8, i.v.) or inverted-ODN (IN-ODN, 200 g per rat, n = 8, i.v.), given with 600 g per rat of liposome DOTAP/DOPE. Hearts from AS-ODN-or IN-ODNtreated rats were excised, perfused in vitro, and subjected to 25 min of global ischemia followed by 30 min of reperfusion. Parallel groups of rats were given ACE inhibitor captopril (5 mg/kg, n = 8) or saline (n = 8) before excising the hearts. Ischemia/reperfusion resulted in myocardial dysfunction (increase in coronary perfusion pressure and LV end-diastolic pressure and a decrease in developed LV pressure) in the saline-treated rats. Myocardial dysfunction was associa-
Introduction
Angiotensin-converting enzyme (ACE) is an important component of the renin-angiotensin system (RAS), which plays a major role in many cardiovascular pathophysiologic processes, such as hypertension, heart failure and myocardial ischemia. [1] [2] [3] [4] ACE gene deletion polymorphism, which relates to a high plasma level of ACE, has been reported to be associated with a high risk of myocardial infarction and sudden death. [5] [6] [7] [8] Many studies show that ACE activity and angiotensin-II (Ang-II) levels increase in plasma after acute myocardial ischemia, which may lead to exacerbation of myocardial ischemia, cardiac dysfunction and expansion of infarct size. 4, [9] [10] [11] A large body of data indicates that ACE inhibitors protect myocardium against ischemia/reperfusion in in vitro and in vivo animal models. [2] [3] [4] [12] [13] [14] ted with evidence of lipid peroxidation and enzyme leakage (MDA and LDH levels in the myocardium) and up-regulation of ACE protein expression. Administration of AS-ODN or captopril, but not IN-ODN, reduced Ang-II levels in the plasma, decreased ischemia/reperfusion-mediated cardiac functional deterioration and lipid peroxidation, and preserved LDH in the myocardium (all P Ͻ 0.05 versus the saline group). AS-ODN and captopril had equipotent effects on cardiac dynamics. ACE protein expression (Western blot) was decreased in the hearts of the AS-ODN-treated group, but not in IN-ODN-treated rat hearts. In contrast, ACE protein expression was significantly increased in captopril-treated rat hearts. These observations suggest that AS-ODN directed at ACE mRNA can ameliorate myocardial dysfunction and injury after ischemia/reperfusion, and its use is associated with decreased expression of ACE protein in the ischemic myocardium. Gene Therapy (2001) 8, 804-810.
also confirmed that the use of ACE inhibitors can prevent recurrent myocardial infarction, reduce infarct zone, improve left ventricular dysfunction and inhibit myocardial remodeling after myocardial infarction. 15, 16 Although chemical ACE inhibitors are commonly used in the treatment of ischemic heart disease, hypertension and heart failure, these agents have several disadvantages such as unpleasant side-effects and need for frequent intake. Recent progress in molecular biology has led to the development of gene therapy as a potential treatment strategy for hypertension and atherosclerosis. 17 Gene therapy may also have application in clinical cardiac transplantation. 18, 19 Development of antisense oligodeoxynucleotides (AS-ODN), as a method of gene therapy, against specific receptor mRNA is a novel approach to decrease the synthesis of receptor protein. 20, 21 This approach has the potential to be of therapeutic benefit in disease states characterized by up-regulation of these receptors. [21] [22] [23] AS-ODN has a prolonged effect 24 and may be devoid of side-effects observed with chemical inhibitors. A recent study from our group indicated that AS-ODN directed at Ang-II type 1 (AT 1 ) receptor mRNA can decrease the synthesis of the AT 1 receptor protein and protect myocardium from the adverse effects of ischemia/reperfusion. 25 Similar observations relative to the beneficial effect of AS-ODN directed at ␤ 1 -adrenoceptor mRNA in myocardial ischemia/reperfusion have also been made. 26 We hypothesized that the use of AS-ODN directed at ACE mRNA (ACE-AS-ODN) might protect myocardium against injury and dysfunction induced by ischemia/reperfusion. We also hypothesized that ACE-AS-ODN might modulate plasma Ang-II levels, myocardial lipid peroxidation and injury, and myocardial expression of ACE protein and mRNA after ischemia/reperfusion. This study was conducted to test these hypotheses.
Results
Uptake of ACE-AS-ODN by the cardiac tissues The FITC-conjugated ACE-AS-ODN was taken up extensively by the cardiac tissues after intravenous injection. A photomicrograph of a 20 m section of the heart is shown in Figure 1 . Immunostaining showed that the AS-ODN uptake was limited to cardiac smooth muscle cells.
Cardiac dysfunction during ischemia/reperfusion
The basal values of CPP, LVEDP, and dLVP were similar in all groups of rat hearts. In the control continuously buffer-perfused hearts observed for 75 min (n = 6), there were only minimal (ෂ5%) changes in the indexes of cardiac function. In the hearts from saline-treated rats (n = 8), 25 min of ischemia followed by 30 min of reperfusion resulted in marked cardiac dysfunction, indicated by a significant increase in CPP and LVEDP, and a decrease in dLVP (all P Ͻ 0.01, versus pre-ischemia values) (Figure 2) .
Treatment of rats with ACE-AS-ODN (n = 8) markedly attenuated ischemia/reperfusion-induced myocardial dysfunction, as indicated by preservation of dLVP and minimization of increase in LVEDP and CPP (all P Ͻ 0.05, versus the saline group). Treatment of rats with captopril (n = 8) also reduced the increase in CPP and LVEDP induced by ischemia/reperfusion (all P Ͻ 0.05, versus the saline-treated group), and attenuated the ischemia/reperfusion-induced change in dLVP (P Ͻ 0.05 versus the saline-treated group). AS-ODN treatment was as effective as captopril treatment in preserving dLVP after ischemia/reperfusion. Treatment with IN-ODN showed no effect on ischemia/reperfusion-induced myocardial dysfunction. Data on cardiac function parameters from multiple experiments are summarized in Figure 2 .
MDA and LDH levels in the myocardium As shown in Figure 3 , MDA levels in the myocardium increased after ischemia/reperfusion (P Ͻ 0.05 versus sham control hearts, n = 7). Pretreatment of rats with AS-ODN or captopril attenuated the increase in MDA levels in the myocardium (both P Ͻ 0.05 versus saline-treated, As also shown in Figure 3 , LDH levels in the myocardium decreased after ischemia/reperfusion (P Ͻ 0.05, versus sham control hearts, n = 7). Pretreatment of rats with either ACE-AS-ODN and captopril, but not IN-ODN, ameliorated the decrease in LDH levels in the myocardium induced by ischemia/reperfusion (both P Ͻ 0.05, versus saline-treated hearts, n = 7).
Ang-II levels in plasma
As shown in Figure 4 , pretreatment with either ACE-AS-ODN or captopril decreased Ang-II levels in rat plasma (both P Ͻ 0.05, versus saline-treated rats, n = 5 each). Ang-II levels in plasma were not affected by pretreatment with IN-ODN. Expression of ACE protein and mRNA in the myocardium Western analysis of the myocardial tissues from control continuously perfused hearts showed a distinct ACE protein band of 170 kDa. A similar molecular weight band was observed in hearts from saline-, AS-ODN-, IN-ODNand captopril-treated rat hearts. The ACE protein band was very dense in the saline-treated rat hearts, indicating up-regulation of the protein during ischemia/ reperfusion. Pretreatment of rats with AS-ODN abolished the ischemia/reperfusion-mediated increase in ACE protein expression. Notably, treatment of rats with IN-ODN had no effect on the level of ACE protein. However, pretreatment of rats with captopril further augmented ACE protein expression in myocardium. Results of representative experiments (from three independent experiments) are presented in Figure 5 .
Ischemia/reperfusion did not affect ACE mRNA signal (adjusted for GAPDH signal) in the myocardium of saline-treated rats, as determined by RT-PCR. ACE mRNA level in the myocardium was also not significantly affected by pretreatment of rats with ACE-AS-ODN, IN-ODN or captopril ( Figure 5 ).
Discussion
The study confirmed that a brief period of ischemia (25 min) followed by reperfusion (30 min) results in significant cardiac dysfunction and myocardial lipid peroxidation and enzyme leakage. We also demonstrated that ischemia/reperfusion is associated with marked up-regulation of the ACE protein expression. The present study is the first to show the protective role of AS-ODN directed at ACE mRNA against myocardial injury and dysfunction after a short period of ischemia/reperfusion. We observed similar cardioprotective effects of pretreatment of rats with ACE-AS-ODN and with the ACE inhibitor captopril. Pretreatment of rats with captopril It is well known that ACE activity in the myocardium and Ang-II levels in plasma and cardiac tissues increase after acute myocardial ischemia. [1] [2] [3] [4] Increased ACE activity also leads to increased breakdown of bradykinin. These neuro-hormonal changes may exacerbate myocardial ischemia and cause expansion of the infarcted area.
4,9-11 Passier et al 27 showed increased ACE activity in the infarcted myocardium at 7-90 days after myocardial infarction in a rat model of myocardial infarction. Whereas long-term therapy with chemical ACE inhibitors has a salutary effect on the indices of myocardial function and remodeling, it can also augment ACE level in plasma and myocardium by a feedback up-regulatory mechanism. [28] [29] [30] In accordance with this concept, the present study clearly shows that ACE protein (measured by Western blot) increases in the hearts from saline-treated rats subjected to ischemia/reperfusion, and pretreatment of rats with the ACE inhibitor captopril further augments ACE protein expression. On the other hand, treatment of rats with ACE-AS-ODN, but not IN-ODN, attenuates the increased ACE protein expression after ischemia/ reperfusion. Pretreatment with ACE-AS-ODN markedly decreased Ang-II levels in plasma in concert with decreased ACE expression. These observations suggest important differences in the mechanism of cardioprotection by ACE-AS-ODN and captopril. ACE-AS-ODN inhibited ACE activity by reducing ACE protein expression, whereas captopril enhanced ACE expression. While the chemical inhibitors of ACE acutely may lower plasma Ang-II levels, this may not be the case upon longterm therapy when the Ang II levels begin to rise.
31, 32 The rise in Ang-II levels may be a reflection of either increased ACE activity or conversion of Ang-I to Ang-II by ACE-independent pathways. 33, 34 Change in ACE mRNA gene expression is a result of regulation of ACE at genomic level in pathophysiologic processes. Passier et al 27 showed that ACE mRNA increased several fold on the 4th and 7th day after myocardial infarction. Notably, chronic use of chemical ACE inhibitors can also increase ACE mRNA level in heart, lung, duodenum, and aorta by feedback regulation. 30, 34, 35 We found that ACE mRNA expression measured by RT-PCR did not increase in the myocardium immediately after ischemia/reperfusion. Pretreatment with captopril also did not affect the level of ACE mRNA in myocardium. These observations suggest that the increase in ACE protein expression in myocardium after a brief period of ischemia (25 min) and reperfusion (30 min) and with treatment with captopril is possibly mediated by an increase in ACE mRNA translation, and not by ACE mRNA transcription. Importantly, we did not observe any effect of ACE-AS on ACE mRNA, yet there was a marked decrease in the ACE protein expression, which indicates that the mechanism by which ACE-AS reduces ACE protein involves the post-transcriptional process. 20 A number of experimental and clinical studies show that ACE inhibitors are beneficial in treating acute myocardial infarction, and the benefits include preservation of left ventricular function 12, 16 and myocardial cell integGene Therapy rity, 13, 36 and reduction in reperfusion arrhythmias 15, 16, 37 and remodeling of myocardium. 36, 38 However, chemical ACE inhibitors have several disadvantages, which include unpleasant side-effects 39 and need for frequent intake. Chronic use of these ACE inhibitors may increase plasma Ang-II levels with potential adverse effects on cardiac hemodynamics. 30 Since ACE-AS reduced ACE protein expression and plasma Ang-II levels and preserved cardiac function after ischemia-reperfusion, we believe that ACE-AS specifically targets ACE protein, and hence, its use may be devoid of traditional side-effects of ACE inhibitors.
AS-ODN has been thought of as an effective approach of gene therapy. 18, 20, 23 In a pharmacokinetic study on the distribution of phosphorothioates after intravenous injection ODN, Sands et al 40 showed that the amount in the heart was 62% (26% in the blood) after 1 min, 51% (0.6% in the blood) after 1 h, and 35% (0.3% in the blood) after 24 h. In a two-compartmental intravenously bolus model, Zhang et al 41 showed half-lives of phosphorothioate to be 5.2 h and 119.3 h in the heart. In additional experiments reported in this study, we showed that ACE-AS-ODN are taken-up by the heart at 4 h after intravenous injection, and the uptake is primarily by myocytes. All these data indicate that phosphorothioated ODN can be effectively taken-up by cardiac tissues and have relatively good stability.
The vector used for carrying ACE-AS-ODN into the myocardium was DOTAP/DOPE liposome, which has been reported to enhance the uptake of AS-ODN by tissues. 24, 25 Recent studies from our laboratory have shown that a single intravenous injection of AS-ODN directed at ␤ 1 -adrenoceptor mRNA, with DOTAP/DOPE liposome as vector, results in sustained beneficial effect of lowering blood pressure for at least 18 days in the SHR. 24 Other studies have shown that AS-ODN directed at AT 1 -receptor mRNA, with DOTAP/DOPE liposome as vector, is taken up by the myocardial tissues and protects against ischemia/reperfusion injury in the rat heart. 25 The present observations also indicate that ACE-AS-ODN, when given with liposomes, can provide a longlasting effect. Thus a gene therapy-based approach may be more advantageous than chemical agents in diseases which need to be treated with ACE inhibitors for a long period. We gave a single dose of ACE-AS 24 h before excising the heart for ischemia-reperfusion studies. This period allowed for adequate uptake of the AS-ODN by the myocardial tissue. On the other hand, captopril was given only 4 h before excising the heart because this agent has a short half-life in plasma.
Besides inhibiting ACE, the ACE inhibitors exert modest antioxidant activity. 42, 43 In the present study, ischemia/reperfusion increased lipid peroxidation and myocardial cell injury, as indicated by an increase of MDA level and a reduction of myocardial LDH content, respectively. Pretreatment with captopril attenuated lipid peroxidation and cell injury in the isolated rat hearts. ACE-AS-ODN, but not IN-ODN, also inhibited lipid peroxidation and diminished cell injury after ischemia/ reperfusion.
In this study, ischemia-reperfusion-induced cardiac dysfunction was evaluated by the measurement of CPP, LVEDP and dLVP. These indices of myocardial dysfunction have been used in several studies in the isolated heart model of global ischemia-reperfusion. 25 ,30,36 Iso-lated rat heart model provides an inexpensive and reproducible method to evaluate cardiac function and myocardial metabolic alterations during ischemia-reperfusion. Others and ourselves have used this model extensively to study regulation of a variety of receptors and modulation of cardiac function by different agents. 13, 25, 26 In the isolated beating heart, cardiac function can be assessed independently of the influence of circulating blood cells and hormones, which may be considered an important advantage of this model. MDA, a lipid peroxidation product, and LDH, an enzyme in the cellular plasma, have also been previously used as indexes of tissue injury after ischemia/reperfusion. 44 Since this study was carried out in an isolated heart preparation, the peripheral effects of AS-ODN were not taken into account. As such, the role of peripheral factors in the preservation of cardiac function cannot be ascertained from the present study.
In summary, the present study shows the amelioration of cardiac dysfunction and myocardial injury induced by ischemia/reperfusion in isolated rat heart with a single intravenous injection of AS-ODN directed at ACE mRNA. This study also provides direct evidence that the AS-ODN can block the augmented expression of ACE protein in the ischemic myocardium.
Materials and methods
ODN and vector liposome ACE antisense ODN (ACE-AS-ODN) was designed to target second zinc-binding domain of ACE mRNA, as described previously. 45 Antisense (AS-ODN) sequence was 13-mer: 5′-ATTTCGTGGTGGG-3′ (position 2998-3010 in rat sequence, according to Ref. 46) . As a control, inverted (IN-ODN) sequence used was: 5′-GGGT GGTGCTTTA-3′. Both sequences were full phosphorothioates, synthesized on commercial synthesizer and desalted.
Two hundred g of ODNs and 600 g of liposomes were injected into each animal. Two hundred g of lyophilized ODN was dissolved in 20 l sterile water and mixed with 480 l of sterile 5% dextrose. Six hundred g of liposomes N-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTAP) and dioleoyl phosphatidylethanolamine (DOPE), 1:1(w/w) 2 mg/ml total lipid in 5% sterile dextrose (300 l total volume) was mixed gently with ODN and injected into the animals.
Animals
Male Sprague-Dawley rats weighing 200-250 g were injected intravenously with either AS-ODN (n = 8) or IN-ODN (n = 8) at a dose of 200 g per rat 24 h before excising the hearts. DOTAP/DOPE liposomes (600 g per rat) were given along with ODN. Parallel groups of rats were treated with saline (n = 16), or the ACE inhibitor captopril 5 mg/kg (n = 8) 4 h before the hearts were excised. This study was approved by the appropriate institutional animal research committees and complied with American Physiological Society guidelines.
Isolated perfused heart model
All rats were anesthetized with sodium pentobarbital (40 mg/kg) intraperitoneally. Blood was drawn for measurement of Ang-II levels in plasma. The hearts were excised rapidly and placed in ice-cold Kreb-Henseleit buffer (mmol/l: NaCl 118, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 1.25, NaHCO 3 25, and glucose 11, pH 7.4). Within 1 min, the hearts were transferred to an isolated perfusion apparatus and perfused via the aorta with oxygen-saturated (95% O 2 + 5% CO 2 ) Kreb-Henseleit buffer kept at 37°C with the use of a MasterFlex pump (ColePalmer Instrument Co, Barrington, IL, USA) according to the modified Langendorff procedure. 25, 26, 47 The heart was placed in a semiclosed circulating water-warmed (37°C) air chamber, paced atrially with a Medtronic 5320 pacemaker (Minneapolis, MN, USA) at a rate of 300 b.p.m., and perfused at a constant flow (5.5-6.0 ml/min). Coronary perfusion pressure (CPP) was measured via a catheter placed just proximal to the aorta and connected to a Gould Statham (Landing, NJ, USA) P23ID pressure transducer. A latex balloon filled with water and connected to a Gould Statham P23ID pressure transducer was inserted into the left ventricle through the left atrium to measure left ventricular end-diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP), and developed left ventricular pressure (dLVP) (dLVP = LVSP − LVEDP). LVEDP during equilibration was set at 5 to 7 mmHg. All measurements were continuously recorded on a 4-channel recorder (Astro-Med, West Warwick, RI, USA).
Myocardial ischemia and reperfusion
Six hearts from saline-treated rats were continuously perfused with Kreb-Henseleit buffer for 75 min and served as sham control. Hearts from other rats, after 20 min of equilibration, were subjected to 25 min of ischemia followed by 30 min of reperfusion. After completion of experiment, hearts were frozen in liquid-nitrogen for ACE protein analysis by Western blot analysis, ACE mRNA analysis by reverse transcription-polymerase chain reaction (RT-PCR), and measurement of MDA and LDH.
Quantification of ACE protein expression in the myocardium Myocardial tissues were homogenized and lysed in boiling lysis buffer (1% SDS, 0.1% Triton X-100, and 10 mmol/l Tris-HCl, pH 7.4) and centrifuged at 10 000 r.p.m. for 30 min at 4°C. The lysate protein from myocardial tissues (20 g per lane) was separated by 8% SDS-PAGE using a Bio-Rad (Hercules, CA, USA) MiniProtean cell, transferred to nitrocellulose membrane (Amersham, Arlington Heights, IL, USA). After incubation in blocking solution (5% non-fat milk; Sigma, St Louis, MO, USA), membranes were incubated with 1:1000 dilution primary antibody (polycolonal antibody to ACE; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for overnight at 4°C. Membranes were washed and incubated with 1:2000 dilution second antibody (Amersham) for 1 h. The membranes were detected with the ECL system, as described previously. 25, 48 Determination of ACE mRNA Total RNA was isolated from rat myocardium with the single step acid-guanidinum thiocyanate-phenol-chloroform method and quantified. 49 One g of total RNA was reverse transcripted with oligo-dT (Promega, Madison, WI, USA ) and M-MLV reverse transcriptase (Promega) at 37°C for 1 h. 1.5 l of RT material was amplified with Taq DNA polymerase (Promega) using a primer pair specific to ACE (forward primer: 5′-CAGCTTCAT-CATCCAGTTCC-3′, reverse primer: 5′-CTAGGAA-GAGCAGCACCCAC-3′). PCR product was 406 base pairs. For PCR, 30 cycles were used at 94°C for 1 min, 62°C for 1 min, and 72°C for 1 min. The RT-PCR amplified samples were visualized on 1.5% agarose gel using ethidium-bromide. A primer pair of rat GAPDH was used as control (forward primer: 5′-ATCAAAT GGGGTGCTGGTGCT-3′, and reverse primer: 5′-CAGGTTTCTCCAGGCGGCATGTCA-3′). For PCR, 35 cycles were used at 95°C for 1 min, 60°C for 1 min, 72°C for 1 min. PCR product was 504 base pairs. Relative intensity of bands of interest were analyzed by NSF-300G Scanner (Microtek, San Clemente, USA). 25, 44, 48 Determination of MDA and LDH Levels in the myocardium Malondialdehyde (MDA) levels in the myocardium were measured in duplicate by modification of the method of Ohkawa et al. 50 Briefly, the ventricular tissues were homogenized. The assay mixture consisted of 0.1 ml of the tissue homogenate, 0.4 ml of 0.9% NaCl, 0.5 ml of 3% sodium dodecylsulfate, 3 ml of TBA (thiobarbituric acid reagent, containing equal parts of 0.8% aqueous thiobarbituric acid and acetic acid) and was heated for 75 min at 95°C. Thereafter, 1 ml cold 0.9% NaCl was added to the mixture, which was cooled and extracted with 5 ml n-butanol. After centrifugation at 3000 r.p.m. for 15 min, the butanol phase was assayed spectrophotometrically at 532 nm. Tetramethoxypropane (in amounts of 0, 0.1, 0.2, 0.4, 0.8, 1.0 nmole) served as external standard. MDA levels in the myocardium were expressed as mol/g tissue.
Twenty l of homogenized tissue from each rat heart sample was used for determination of lactate dehydrogenase (LDH). A spectrophotometric enzyme activity method based on the oxidation of lactate was used (Sigma). LDH activity was expressed as units per gram tissue weight. 44 Plasma angiotensin-II levels Angiotensin peptides were extracted from 3-4 ml of plasma with an equal volume of a mixture of acetone, 1 m HCl, and distilled water (40:1:10 by volume). Samples were centrifuged (6000 g, 4°C, 10 min) and the pellet was re-extracted with 1 ml of the extraction medium and centrifuged again under the same conditions. Both supernatants were pooled and the samples were dried in a vacuum centrifuge at 60°C. The dried samples were dissolved in 0.5 ml RIA buffer and centrifuged (10 000 g, 20°C, 2 min) before the radioimmunological measurement of Ang-II. The analytical recoveries of 125I -labeled Ang-II were 69 ± 2% (n = 7). 51 Antisense uptake by the heart tissue In order to determine the uptake of AS-ODN by cardiac tissues, 40 g of ACE-AS ODN, phosphorothioated and conjugated with fluorescein isothiocyanate (FITC) on both 3′ and 5′ ends were mixed with 120 g DOTAP/DOPE liposomes, and then injected into the tongue vein of 127SV/C57BL6 mice. Four hours later, mice were killed and the cardiac tissues were cryostatsectioned into 20 m-thick slices. The slide-mounted heart slices were viewed with a BioRad MRC-1024 laserscanning confocal microscope (Bio-Rad Labs, Hercules, CA, USA). Immunostaining was performed for alphaactin (smooth muscle cells) and fibroblasts.
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Data analysis
Data are presented as mean ± s.e.m. Statistical significance was determined in multiple comparisons among independent groups of data in which ANOVA and unpaired t test indicated the presence of significant differences. A P value of Ͻ0.05 was considered statistically significant.
